Richard J. Honeywell

Author

Amsterdam UMC Location Vrije Universiteit Amsterdam ORCID

Also Known As

R Honeywell, R. HONEYWELL, R. Honeywell, R. J. Honeywell, R.J. Honeywell, RG Honeywell, Richard Honeywell, Richard J Honeywell, Richard J. Honeywell

161

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam University of Southampton Amsterdam University Medical Centers The Netherlands Cancer Institute Radboud University Nijmegen

About

Richard J. Honeywell is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	607
2	Biochemistry	6	6	248
3	Cell Biology	5	5	123
4	Natural Sciences	4	4	189
5	Allergy	1	1	11

Richard J. Honeywell

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance Kristy J. Gotink, Henk J. Broxterman, Mariëtte Labots, Clinical Cancer Research	2011	335
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia Mina Maftouh, Abolfazl Avan, Rocco Sciarrillo, British Journal of Cancer	2013	172
Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Amir Avan, Francesco Crea, Elisa Paolicchi, Molecular Cancer Therapeutics	2012	97
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry Richard J. Honeywell, K. Yarzadah, Elisa Giovannetti, Journal of Chromatography B Medicinal ChemistryBiochemistryMedicineDrug DiscoveryBioanalysis	2010	93
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer J. Sigmond, Richard J. Honeywell, Tjeerd J. Postma, Annals of Oncology Neuro-oncologyRadiation TherapyGliomaMedicineGemcitabine Uptake	2008	89
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma Amir Avan, Viola Caretti, Niccola Funel, Cancer Research	2013	88
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer Joline S.W. Lind, Anne‐Marie C. Dingemans, Harry J.M. Groen, Clinical Cancer Research	2010	85
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib Kristy J. Gotink, Maria Rovithi, Richard R. de Haas, Cellular Oncology	2015	57
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients Carmelo Tibaldi, Elisa Giovannetti, Marcello Tiseo, Annals of Oncology Clinical OutcomeMedicinePathologyBronchial NeoplasmCytidine Deaminase Polymorphisms	2011	57
Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine Richard J. Honeywell, Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, The International Journal of Biochemistry & Cell Biology Medicinal ChemistryBiochemistryNatural SciencesThymidylate SynthaseChemical Biology	2015	51

Page 1